Long Term Impact of Adalimumab Therapy on Biomarkers of Systemic Inflammation in Psoriasis: Results of a 2 year study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43920316" target="_blank" >RIV/00216208:11120/20:43920316 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/20:N0000028

Výsledek na webu

<a href="https://doi.org/10.1111/dth.14110" target="_blank" >https://doi.org/10.1111/dth.14110</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dth.14110" target="_blank" >10.1111/dth.14110</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Long Term Impact of Adalimumab Therapy on Biomarkers of Systemic Inflammation in Psoriasis: Results of a 2 year study

Popis výsledku v původním jazyce

Psoriasis patients are at increased risk of atherosclerosis, characterized by endothelial dysfunction, linked through systemic inflammation. Anti-TNF-a therapy seems to decrease this risk. The purpose of this study was to measure the levels of serum markers associated with systemic inflammation in psoriasis patients, compared to healthy individuals and to investigate the change in their levels after 3 months and 2 years of adalimumab therapy. We investigated 4 biomarkers: high-sensitivity C-reactive protein (hsCRP), oxidized low-density lipoproteins (OxLDL), E-selectin and Interleukin 22 (IL-22). These markers were measured in healthy volunteers and in 28 patients with moderate/severe psoriasis before and after 3 and 24 months of treatment with adalimumab. Psoriasis patients had increased levels of markers in comparison to the control group. After 3 months of therapy, E-selectin decreased significantly (P &lt; 0.001), as well as IL-22 (P &lt; 0.001). hsCRP also decreased but did not show a statistical significance, OxLDL were slightly higher than initially. After 24 months, 17 patients were still being treated with adalimumab. In these patients, hsCRP (P &lt; 0.05), E-selectin (P &lt; 0.001) and IL-22 (P &lt; 0.001) were significantly decreased. OxLDL remained at a higher level. The stable decrease of E-selectin, hsCRP and IL-22 after 24 months confirms that adalimumab suppresses systemic inflammation.

Název v anglickém jazyce

Long Term Impact of Adalimumab Therapy on Biomarkers of Systemic Inflammation in Psoriasis: Results of a 2 year study

Popis výsledku anglicky

Psoriasis patients are at increased risk of atherosclerosis, characterized by endothelial dysfunction, linked through systemic inflammation. Anti-TNF-a therapy seems to decrease this risk. The purpose of this study was to measure the levels of serum markers associated with systemic inflammation in psoriasis patients, compared to healthy individuals and to investigate the change in their levels after 3 months and 2 years of adalimumab therapy. We investigated 4 biomarkers: high-sensitivity C-reactive protein (hsCRP), oxidized low-density lipoproteins (OxLDL), E-selectin and Interleukin 22 (IL-22). These markers were measured in healthy volunteers and in 28 patients with moderate/severe psoriasis before and after 3 and 24 months of treatment with adalimumab. Psoriasis patients had increased levels of markers in comparison to the control group. After 3 months of therapy, E-selectin decreased significantly (P &lt; 0.001), as well as IL-22 (P &lt; 0.001). hsCRP also decreased but did not show a statistical significance, OxLDL were slightly higher than initially. After 24 months, 17 patients were still being treated with adalimumab. In these patients, hsCRP (P &lt; 0.05), E-selectin (P &lt; 0.001) and IL-22 (P &lt; 0.001) were significantly decreased. OxLDL remained at a higher level. The stable decrease of E-selectin, hsCRP and IL-22 after 24 months confirms that adalimumab suppresses systemic inflammation.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Dermatologic Therapy

ISSN

1396-0296

e-ISSN

—

Svazek periodika

33

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

"Article e14110"

Kód UT WoS článku

000560662900001

EID výsledku v databázi Scopus

2-s2.0-85089455762